Chiesi Group agreed to an exclusive collaboration and license with Arbor Biotechnologies to develop Arbor’s ABO‑101, an in‑vivo liver‑directed CRISPR Cas12i2 therapy for primary hyperoxaluria type 1 (PH1), in a deal that could total more than $2.1 billion. The program uses an Acuitas lipid nanoparticle (LNP) to deliver mRNA encoding a Cas12i2 nuclease and an optimized guide RNA targeting HAO1 to permanently knock out hepatic oxalate production. The partners will continue the ongoing Phase I/II redePHine trial (NCT06839235) to evaluate safety, tolerability, PK/PD and target engagement, and Chiesi gains options to access Arbor’s knockout and reverse‑transcriptase editing platforms for other rare liver targets. The agreement marks Chiesi’s first foray into gene editing and positions both companies to accelerate a one‑time editing approach for metabolic liver diseases that require durable target inactivation.